Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elske Quak

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 11, 2016
Does PET SUV Harmonization Affect PERCIST Response Classification?Elske Quak, Pierre-Yves Le Roux, Charline Lasnon, et al.
EJNMMI Physics|June 1, 2017
EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization programCharline Lasnon, Elske Quak, Pierre-Yves Le Roux, et al.
BMC Endocrine Disorders|January 8, 2021
Upfront F18-choline PET/CT versus Tc99m-sestaMIBI SPECT/CT guided surgery in primary hyperparathyroidism: the randomized phase III diagnostic trial APACH2Elske Quak, Audrey Lasne Cardon, Renaud Ciappuccini, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 20, 2024
F18-Choline PET/CT or MIBI SPECT/CT in the Surgical Management of Primary Hyperparathyroidism: A Diagnostic Randomized Clinical TrialElske Quak, Audrey Lasne-Cardon, Marie Cavarec, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
The Lancet. Oncology|August 12, 2024
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [<sup>18</sup>F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trialPierre Vera, Sébastien Thureau, Florence Le Tinier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2025
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung CancerPierre Vera, Philippe Giraud, Sébastien Hapdey, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 11, 2016
Does PET SUV Harmonization Affect PERCIST Response Classification?Elske Quak, Pierre-Yves Le Roux, Charline Lasnon, et al.
EJNMMI Physics|June 1, 2017
EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization programCharline Lasnon, Elske Quak, Pierre-Yves Le Roux, et al.
BMC Endocrine Disorders|January 8, 2021
Upfront F18-choline PET/CT versus Tc99m-sestaMIBI SPECT/CT guided surgery in primary hyperparathyroidism: the randomized phase III diagnostic trial APACH2Elske Quak, Audrey Lasne Cardon, Renaud Ciappuccini, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 20, 2024
F18-Choline PET/CT or MIBI SPECT/CT in the Surgical Management of Primary Hyperparathyroidism: A Diagnostic Randomized Clinical TrialElske Quak, Audrey Lasne-Cardon, Marie Cavarec, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
The Lancet. Oncology|August 12, 2024
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [<sup>18</sup>F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trialPierre Vera, Sébastien Thureau, Florence Le Tinier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2025
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung CancerPierre Vera, Philippe Giraud, Sébastien Hapdey, et al.
Pageof 4